Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sparsentan in Stage I and II Hypertension
NCT00522925Phase 2Completed
- Sponsor
- Ligand Pharmaceuticals
- Start
- Aug 2007
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sparsentan in hypertension (HTN) (3 arms), sponsored by Ligand Pharmaceuticals. Primary endpoint: Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure at 4 weeks. Started Aug 2007; status: completed.
02
Drugs
sparsentan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00522925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00522925.